Objective: This study assessed conversion factors utilized by physicians to transfer postoperative patients from intravenous opioids to oral controlled-release (CR) oxycodone and the subsequent analgesic effectiveness.
Design: This was a multicenter, open-label, usual-use study of 189 hospitalized postoperative patients receiving opioid (usually morphine) intravenous patient-controlled analgesia (IV PCA) for at least 12 to 24 hours post-procedure. Patients who were tolerant of oral medications and without signs of paralytic ileus were converted to oral CR oxycodone, given every 12 hours for up to 7 days.
Results: The mean (+/-SE) conversion factor used to convert IV PCA morphine to CR oxycodone was 1.2 +/- 0.1 (N=159). The initial CR oxycodone doses, based on individual conversion factors from IV PCA morphine, produced significant reductions in pain intensity (scores
Conclusions: Administered at least 12 hours following abdominal, orthopedic, or gynecologic surgery, an initial oral CR oxycodone dose calculated by multiplying the amount of IV morphine used in the previous 24 hours (immediate postoperative period) by a conversion factor of 1.2, on average, provided adequate pain control during the subsequent 12-hour dosing interval and for a maximum of 7 days. Adverse events were consistent with opioid side effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1526-4637.2003.03004.x | DOI Listing |
J Nanobiotechnology
December 2024
Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, 04510, Ciudad de Mexico, Mexico.
Diabetes mellitus (DM) prevalence is rising worldwide. Current therapies comprising subcutaneous insulin injections can cause adverse effects such as lipodystrophy, local reactions like redness and swelling, fluid retention, and allergic reactions. Nanoparticle carriers for oral insulin are groundbreaking compared to existing methods because they are non-invasive treatments, showing operational convenience, controlled release profile, and ability to simulate the physiological delivery route into the bloodstream.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
Department of Biotechnology, Science Campus, Alagappa University, Karaikudi 630 003, Tamil Nadu, India. Electronic address:
Bacteriophages hold promise for combating pathogenic bacteria in the human intestinal tract, but their therapeutic potential is limited by harsh stomach conditions, including low pH and digestive enzymes. This study aimed to develop a natural protective mechanism for orally administering phages to treat gastric infections caused by Klebsiella aerogenes. Results revealed that free phages became inactive at pH 3 without protective measures.
View Article and Find Full Text PDFInt J Pharm
December 2024
Department of Pharmaceutical Engineering, Azrieli College of Engineering Jerusalem, Jerusalem 9103501, Israel. Electronic address:
Chlorhexidine (CHX) is a gold standard therapeutic agent against clinical oral pathogens. However, its oral use is limited due to unpleasant taste, alteration in taste buds, staining of teeth and mucous membranes. Therefore, CHX-loaded PLGA microneedles (MNs) were fabricated for local and controlled release in the oral cavity, using a casting mold method.
View Article and Find Full Text PDFJ Food Sci
December 2024
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.
Vitamin B, or riboflavin, is essential for maintaining healthy cellular metabolism and function. However, its light sensitivity, poor water solubility, and gastrointestinal barriers limit its storage, delivery, and absorption. Selecting suitable nanomaterials for encapsulating vitamin B is crucial to overcoming these challenges.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
College of Biosystems Engineering & Food Science, Zhejiang University, Hangzhou 310058, China. Electronic address:
pH changes occur during bodily lesions, presenting an opportunity for leveraging pH-responsive delivery systems as signals for a targeted response. This review explores the design and application of pH-responsive delivery systems based on natural polysaccharides for the controlled release of bioactives. The article examines the development of diverse delivery carriers, including nanoparticles, nanofibers, nanogels, core-shell carriers, hydrogels, emulsions as well as liposomes and their capacity to respond to pH variations, enabling the precise and targeted delivery of bioactives within the human body.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!